Saltar al contenido
Merck
Todas las fotos(1)

Key Documents

View All Documentation

D9302

Sigma-Aldrich

Diacerein

≥95% (HPLC)

Sinónimos:

1,8-Diacetoxy-3-carboxyanthraquinone

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

Fórmula empírica (notación de Hill):
C19H12O8
Número de CAS:
13739-02-1
Peso molecular:
368.29
EC Number:
237-310-2
MDL number:
MFCD00468030
UNSPSC Code:
41116107
PubChem Substance ID:
24894281
NACRES:
NA.25

assay

≥95% (HPLC)

form

powder

SMILES string

CC(=O)Oc1cccc2C(=O)c3cc(cc(OC(C)=O)c3C(=O)c12)C(O)=O

InChI

1S/C19H12O8/c1-8(20)26-13-5-3-4-11-15(13)18(23)16-12(17(11)22)6-10(19(24)25)7-14(16)27-9(2)21/h3-7H,1-2H3,(H,24,25)

InChI key

TYNLGDBUJLVSMA-UHFFFAOYSA-N

¿Está buscando productos similares? Visita Guía de comparación de productos

Biochem/physiol Actions

Diacerin is an inhibitor of Interleukin-1B (IL-1B) production.

pictograms

Exclamation mark
GHS07

signalword

Warning

Hazard Classifications

Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

target_organs

Respiratory system

Storage Class

11 - Combustible Solids

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

dust mask type N95 (US), Eyeshields, Gloves

Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Amit Kumar Aggarwal et al.
Drug development and industrial pharmacy, 37(10), 1181-1191 (2011-04-01)
Diacerein (DCN) is a new anti-inflammatory analgesic and antipyretic drug developed specially for the treatment of osteoarthritis. DCN is a poorly water-soluble drug with relatively low bioavailability. Therefore, the purpose of this study was to enhance the solubility and dissolution
P Härle et al.
Der Internist, 49(12), 1458-1462 (2008-11-18)
There is an increasing incidence in osteoarthritis, particularly following the 5th life-decade. However, also young people may suffer from severe osteoarthritis, which is estimated to be the most common cause of disability in adults resulting in substantial economic burden. To
Olivier Bruyère et al.
BMC musculoskeletal disorders, 9, 165-165 (2008-12-18)
Symptomatic slow-acting drugs (SYSADOA) have been largely studied over the last decade. The objective of this study is to prepare a document providing recommendations for the use of SYSADOA in osteoarthritis (OA). The following interventions were taken into consideration: avocado/soybean
Pascal Richette
La Revue du praticien, 62(5), 654-660 (2012-06-27)
According to the European League of Associations of Rheumatology (EULAR) and the American College of Rheumatology (ACR), acetaminophen should be used as a first-line therapy in patients with osteoarthritis, because of its safety and effectiveness. NSAID should be considered in
Umut Kalyoncu et al.
Joint, bone, spine : revue du rhumatisme, 76(4), 389-393 (2009-02-17)
The objective of the present study was to assess the frequency of self-reported psoriasis in a hip osteoarthritis (OA) cohort, and a secondary objective was to assess the course of hip OA with psoriasis. ECHODIAH was a 3-year, randomised double-blind
Ver todos los artículos relacionados

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico